"Nitrobenzoates" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Benzoic acid or benzoic acid esters substituted with one or more nitro groups.
| Descriptor ID |
D009579
|
| MeSH Number(s) |
D02.241.223.100.600 D02.455.426.559.389.127.650
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Nitrobenzoates".
Below are MeSH descriptors whose meaning is more specific than "Nitrobenzoates".
This graph shows the total number of publications written about "Nitrobenzoates" by people in this website by year, and whether "Nitrobenzoates" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 0 | 1 | 1 |
| 1998 | 1 | 1 | 2 |
| 2002 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 2 | 2 |
| 2008 | 0 | 2 | 2 |
| 2016 | 1 | 1 | 2 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Nitrobenzoates" by people in Profiles.
-
Ex vivo gene editing and cell therapy for hereditary tyrosinemia type 1. Hepatol Commun. 2024 05 01; 8(5).
-
Inhibition of the apelin/apelin receptor axis decreases cholangiocarcinoma growth. Cancer Lett. 2017 02 01; 386:179-188.
-
Reprogramming metabolic pathways in vivo with CRISPR/Cas9 genome editing to treat hereditary tyrosinaemia. Nat Commun. 2016 08 30; 7:12642.
-
Activation of nuclear factor E2-related factor 2 in hereditary tyrosinemia type 1 and its role in survival and tumor development. Hepatology. 2008 Aug; 48(2):487-96.
-
Loss of p21 permits carcinogenesis from chronically damaged liver and kidney epithelial cells despite unchecked apoptosis. Cancer Cell. 2008 Jul 08; 14(1):59-67.
-
Hepatic stress in hereditary tyrosinemia type 1 (HT1) activates the AKT survival pathway in the fah-/- knockout mice model. J Hepatol. 2008 Feb; 48(2):308-17.
-
Rescue from neonatal death in the murine model of hereditary tyrosinemia by glutathione monoethylester and vitamin C treatment. Mol Genet Metab. 2008 Mar; 93(3):306-13.
-
Evaluation of dichloroacetate treatment in a murine model of hereditary tyrosinemia type 1. Biochem Pharmacol. 2006 May 28; 71(11):1648-61.
-
Chronic liver disease in murine hereditary tyrosinemia type 1 induces resistance to cell death. Hepatology. 2004 Feb; 39(2):433-43.
-
Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I. Mol Genet Metab. 2002 Jan; 75(1):38-45.